OncoSec Medical Inc (ONCS) Receives Consensus Rating of “Buy” from Analysts

OncoSec Medical Inc (NASDAQ:ONCS) has been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $2.83.

A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Friday. Maxim Group set a $5.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a research report on Wednesday, December 12th.

A number of large investors have recently added to or reduced their stakes in ONCS. Geode Capital Management LLC lifted its position in shares of OncoSec Medical by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 163,405 shares in the last quarter. Northern Trust Corp lifted its position in shares of OncoSec Medical by 33.6% during the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 28,914 shares in the last quarter. Moloney Securities Asset Management LLC lifted its position in shares of OncoSec Medical by 117.4% during the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 27,000 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of OncoSec Medical by 484.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 83,150 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of OncoSec Medical by 98.2% during the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 240,843 shares in the last quarter. Hedge funds and other institutional investors own 6.41% of the company’s stock.

NASDAQ:ONCS opened at $0.56 on Friday. OncoSec Medical has a 12 month low of $0.42 and a 12 month high of $2.21.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings results on Friday, December 14th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.06. As a group, equities research analysts expect that OncoSec Medical will post -0.74 EPS for the current year.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Further Reading: Investing in Blue-Chip Stocks

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply